UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002593
Receipt number R000003155
Scientific Title Recognized Effect of Statin and Ezetimibe therapy for achievement LDL-C Goal
Date of disclosure of the study information 2009/10/07
Last modified on 2015/03/30 19:39:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Recognized Effect of Statin and Ezetimibe therapy for achievement LDL-C Goal

Acronym

RESEARCH

Scientific Title

Recognized Effect of Statin and Ezetimibe therapy for achievement LDL-C Goal

Scientific Title:Acronym

RESEARCH

Region

Japan


Condition

Condition

type 2 diabetes mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the eficacy of ezetimibe 10mg administered with statin in Japanese patients with type 2 diabetes.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Percent reduction in LDL-C from baseline to study endpoint.

Key secondary outcomes

Percentage of patients who reached the treatment goals (LDL-C 120mg/dl or 100mg/dl).
Percent change of serum lipids, serum markers of glucose metabolism and serum markers of inflammation.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

atorvastatin 10mg and ezetimibe 10mg/
atorvastatin 20mg

Interventions/Control_2

pitavastatin 1mg and ezetimibe 10mg/
pitavastatin 2mg

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Type 2 diabetes.
(2) Serum LDL-C over 120mg/dL after administration of atorvastatin 10mg or pitavastatin 1mg for one month or more.

Key exclusion criteria

(1) History of hypersensitivity to atorvastatin, pitavastatin or ezetimibe
(2) Serum triglyceride level more than 400mg/dl
(3) Hepatic dysfunction (an alanine aminotransferase level that is more than twice the upper limit of the normal range)
(4) Uncontrolled diabetes (HbA1c more than 9.0%)
(5) Renal dysfunction (a creatinine level that is higher than 2.0 mg per deciliter)
(6) Secondary or drug-induced hypercholesterolemia
(7) Homozygous familial hypercholesterolemia
(8) Pregnant or nursing women or women suspect of pregnancy
(9) Judged as inappropriate for study by doctor

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Teruo Shiba

Organization

Mitsui Memorial Hospital

Division name

Department of internal medicine/Division of diabetes and metabolism

Zip code


Address

1 Kandaizumicho, Chiyoda-ku, Tokyo 101-8643, JAPAN

TEL

+81-3-3862-9111

Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Mitsui Memorial Hospital

Division name

Department of internal medicine/Division of diabetes and metabolism

Zip code


Address


TEL


Homepage URL


Email

isogawa-tky@umin.ac.jp


Sponsor or person

Institute

Clinical study group for diabetes and dyslipidemia

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 10 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2009 Year 07 Month 01 Day

Date of IRB


Anticipated trial start date

2009 Year 07 Month 01 Day

Last follow-up date

2011 Year 06 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 10 Month 07 Day

Last modified on

2015 Year 03 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003155


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name
2015/04/01 RESEARCH_dataset.xlsx